| HOME >> BIOLOGY >> TECHNOLOGY |
NASHUA, N.H., Dec. 10 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that two U.S. Patents, No. 7,298,877 and No. 7,308,126, have recently been granted to the Company by the United States Patent and Trademark Office.
"These patent grants demonstrate our on-going commitment to broadening and protecting our intellectual property, and represent an important addition to our portfolio of CAD product and technology patents," said Ken Ferry, President and Chief Executive Officer of iCAD. "The first patent provides an information fusion method for multiple indicators of cancer by using a specific method of combining lesion information, while the second patent addresses improved clinical workflow."
These patent awards bring the number of issued patents in 2007 to four, which includes two patents issued in June related to CAD billing workflow support and CAD for virtual colonoscopy.
iCAD offers high-performance CAD solutions for both digital and film-based mammography systems. Additionally, iCAD is developing CAD solutions for use with virtual colonoscopy to improve the detection of colonic polyps. iCAD's systems are based on sophisticated algorithms that analyze the data, automatically identifying and marking suspicious regions in the images. The result is earlier detection of hard-to-find cancers, improved workflow for radiologists and higher quality patient care.
About iCAD, Inc.
iCAD, Inc. (Nasdaq: ICAD) is an industry-leading provider of Computer-
Aided Detection (CAD) solutions that enable healthcare professionals to
better serve patients by identifying p
'/>"/>
| SOURCE iCAD, Inc. Copyright©2007 PR Newswire. All rights reserved |